Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers

(2019) Man Keung et al.   Journal of Clinical Medicine

XRCC1 protein; Form and function

(2019) Keith W. Caldecott   DNA REPAIR

Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation

(2019) Shuai Wang et al.   Nature Chemical Biology

Fanconi Anemia complementation group C protein in metabolic disorders

(2018) Manoj Nepal et al.   Aging-US

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Homologous recombination and the repair of DNA double-strand breaks

(2018) William Douglass Wright et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Fanconi anemia complementation group C protection against oxidative stress‑induced β‑cell apoptosis

(2018) Sirikul Kulanuwat et al.   Molecular Medicine Reports

Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?

(2018) Alan Ashworth et al.   Nature Reviews Clinical Oncology

CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions

(2018) Michal Zimmermann et al.   NATURE

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

(2018) Jennifer K. Litton et al.   NEW ENGLAND JOURNAL OF MEDICINE

PARPs in genome stability and signal transduction: implications for cancer therapy

(2018) Luca Palazzo et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Hereditary breast cancer; Genetic penetrance and current status with BRCA

(2018) Morteza Mahdavi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow

(2018) Todd A. Hopkins et al.   MOLECULAR CANCER RESEARCH

Therapeutic targeting and patient selection for cancers with homologous recombination defects

(2017) Francien Talens et al.   Expert Opinion on Drug Discovery

A low-frequency haplotype spanning SLX4/FANCP constitutes a new risk locus for early-onset breast cancer (

(2017) Harald Surowy et al.   INTERNATIONAL JOURNAL OF CANCER

The Role of PALB2 in the DNA Damage Response and Cancer Predisposition

(2017) Thales Nepomuceno et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Biallelic mutations in the ubiquitin ligase RFWD3 cause Fanconi anemia

(2017) Kerstin Knies et al.   JOURNAL OF CLINICAL INVESTIGATION

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

(2017) Elizabeth M Swisher et al.   LANCET ONCOLOGY

Activation of the FA pathway mediated by phosphorylation and ubiquitination

(2017) Masamichi Ishiai et al.   MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

Synthetic lethality and cancer

(2017) Nigel J. O'Neil et al.   NATURE REVIEWS GENETICS

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

(2017) Mark Robson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Compromised BRCA1–PALB2 interaction is associated with breast cancer risk

(2017) T K Foo et al.   ONCOGENE

PARP inhibitors: Synthetic lethality in the clinic

(2017) Christopher J. Lord et al.   SCIENCE

Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer

(2017) Guido Neidhardt et al.   JAMA Oncology

Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility

(2017) Tuomo Mantere et al.   Scientific Reports

Interplay between Fanconi anemia and homologous recombination pathways in genome integrity

(2016) Johanna Michl et al.   EMBO JOURNAL

Fanconi anemia with biallelic FANCD1/BRCA2 mutations – Case report of a family with three affected children

(2016) Karel Svojgr et al.   European Journal of Medical Genetics

The role of USP1 autocleavage in DNA interstrand crosslink repair

(2016) Mira Kim et al.   FEBS LETTERS

Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action

(2016) Y. Pommier et al.   Science Translational Medicine

Mutation analysis of PALB2 gene in French breast cancer families

(2015) Francesca Damiola et al.   BREAST CANCER RESEARCH AND TREATMENT

FANCA safeguards interphase and mitosis during hematopoiesis in vivo

(2015) Zahi Abdul-Sater et al.   EXPERIMENTAL HEMATOLOGY

FANCMc.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor

(2015) Paolo Peterlongo et al.   HUMAN MOLECULAR GENETICS

Analysis of PALB2 mutations in 155 Japanese patients with breast and/or ovarian cancer

(2015) Hiroshi Nakagomi et al.   International Journal of Clinical Oncology

Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer

(2015) Timothy R. Rebbeck et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

FANCD2-associated Nuclease 1, but Not Exonuclease 1 or Flap Endonuclease 1, Is Able to Unhook DNA Interstrand Cross-linksin Vitro

(2015) Julia Pizzolato et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

(2015) Joaquin Mateo et al.   NEW ENGLAND JOURNAL OF MEDICINE

PALB2: The hub of a network of tumor suppressors involved in DNA damage responses

(2014) Jung-Young Park et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

BRCA1 and FancJ cooperatively promote interstrand crosslinker induced centrosome amplification through the activation of polo-like kinase 1

(2014) Jianqiu Zou et al.   CELL CYCLE

Signalling dynamics in the spindle checkpoint response

(2014) Nitobe London et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Breast-Cancer Risk in Families with Mutations in PALB2

(2014) Antonis C. Antoniou et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer

(2014) Johanna I. Kiiski et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Biallelic Mutations in BRCA1 Cause a New Fanconi Anemia Subtype

(2014) Sarah L. Sawyer et al.   Cancer Discovery

Fanconi anemia signaling network regulates the spindle assembly checkpoint

(2013) Grzegorz Nalepa et al.   JOURNAL OF CLINICAL INVESTIGATION

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

(2013) J. Murai et al.   MOLECULAR CANCER THERAPEUTICS

Assessment of SLX4 Mutations in Hereditary Breast Cancers

(2013) Sohela Shah et al.   PLoS One

Analysis of PALB2 Gene in BRCA1/BRCA2 Negative Spanish Hereditary Breast/Ovarian Cancer Families with Pancreatic Cancer Cases

(2013) Ana Blanco et al.   PLoS One

A Distinct Replication Fork Protection Pathway Connects Fanconi Anemia Tumor Suppressors to RAD51-BRCA1/2

(2012) Katharina Schlacher et al.   CANCER CELL

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

(2012) S. Kummar et al.   CLINICAL CANCER RESEARCH

p21WAF1 and tumourigenesis

(2012) Noel A. Warfel et al.   CURRENT OPINION IN ONCOLOGY

The role of BRCA1 in DNA double-strand repair: Past and present

(2012) Kevin W. Caestecker et al.   EXPERIMENTAL CELL RESEARCH

Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway

(2012) H. Kim et al.   GENES & DEVELOPMENT

Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families

(2012) Ana Osorio et al.   HUMAN MOLECULAR GENETICS

The DNA translocase activity of FANCM protects stalled replication forks

(2012) Andrew N. Blackford et al.   HUMAN MOLECULAR GENETICS

Analysis of the Novel Fanconi Anemia GeneSLX4/FANCPin Familial Breast Cancer Cases

(2012) Janine L. Bakker et al.   HUMAN MUTATION

Characterization of BRCA1 Protein Targeting, Dynamics, and Function at the Centrosome

(2012) Kirsty M. Brodie et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Structural Basis for DNA Damage-Dependent Poly(ADP-ribosyl)ation by Human PARP-1

(2012) M.-F. Langelier et al.   SCIENCE

Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer

(2012) Susan M. Domchek et al.   Cancer Discovery

Exome Sequencing Identifies Rare Deleterious Mutations in DNA Repair Genes FANCC and BLM as Potential Breast Cancer Susceptibility Alleles

(2012) Ella R. Thompson et al.   PLoS Genetics

Mutation analysis of the SLX4/FANCP gene in hereditary breast cancer

(2011) Rosa Landwehr et al.   BREAST CANCER RESEARCH AND TREATMENT

SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype

(2011) Chantal Stoepker et al.   NATURE GENETICS

Mutations of the SLX4 gene in Fanconi anemia

(2011) Yonghwan Kim et al.   NATURE GENETICS

Involvement of SLX4 in interstrand cross-link repair is regulated by the Fanconi anemia pathway

(2011) K. N. Yamamoto et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

RAD51 paralogs: Roles in DNA damage signalling, recombinational repair and tumorigenesis

(2011) Natsuko Suwaki et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

The Fanconi anemia pathway and DNA interstrand cross-link repair

(2011) Xiaoyu Su et al.   Protein & Cell

Significance of the Fanconi Anemia FANCD2 Protein in Sporadic and Metastatic Human Breast Cancer

(2010) Philip S. Rudland et al.   AMERICAN JOURNAL OF PATHOLOGY

Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors

(2010) A. Mukhopadhyay et al.   CLINICAL CANCER RESEARCH

FANCJ: Solving problems in DNA replication

(2010) Kevin Hiom   DNA REPAIR

Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2

(2010) Nancie Petrucelli et al.   GENETICS IN MEDICINE

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Mutation of the RAD51C gene in a Fanconi anemia–like disorder

(2010) Fiona Vaz et al.   NATURE GENETICS

Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene

(2010) Alfons Meindl et al.   NATURE GENETICS

Susceptibility Pathways in Fanconi's Anemia and Breast Cancer

(2010) Alan D. D'Andrea   NEW ENGLAND JOURNAL OF MEDICINE

Impact of RING and BRCT Domain Mutations on BRCA1 Protein Stability, Localization and Recruitment to DNA Damage

(2010) Andrew C. Nelson et al.   RADIATION RESEARCH

PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response

(2009) Feng Zhang et al.   CURRENT BIOLOGY

Promotion of BRCA1-associated triple-negative breast cancer by ovarian hormones

(2009) Eva Y-HP Lee   CURRENT OPINION IN OBSTETRICS & GYNECOLOGY

The Fanconi Anemia Protein FANCM Is Controlled by FANCD2 and the ATR/ATM Pathways

(2009) Alexandra Sobeck et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PALB2 Functionally Connects the Breast Cancer Susceptibility Proteins BRCA1 and BRCA2

(2009) F. Zhang et al.   MOLECULAR CANCER RESEARCH

Fanconi anemia and its diagnosis

(2009) Arleen D. Auerbach   MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

A mechanism linking extra centrosomes to chromosomal instability

(2009) Neil J. Ganem et al.   NATURE

PALB2 is an integral component of the BRCA complex required for homologous recombination repair

(2009) S. M. H. Sy et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families

(2008) Frédéric Guénard et al.   JOURNAL OF HUMAN GENETICS

Remodeling of DNA replication structures by the branch point translocase FANCM

(2008) K. Gari et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The emerging landscape of breast cancer susceptibility

(2007) Michael R Stratton et al.   NATURE GENETICS